Connect with us

Technology

Complete Genomics Highlights Innovation with Expanded Multi-Omics and Spatial Transcriptomics Applications at ASHG 2024

Published

2 years ago

on

DENVER, Nov. 4, 2024 /PRNewswire/ — At the American Society of Human Genetics (ASHG) Annual Meeting (Nov. 5-9, 2024), Complete Genomics, a pioneering genomic sequencing company, will highlight an expanded application menu and broader market adoption of its flagship sequencer DNBSEQ-T7 ™ and a series of product launches and new innovations.

Over the last year, Complete Genomics’ flagship sequencer, DNBSEQ-T7 has gained more adoption in the market for its flexibility, catering to the industry trend of sequencing more modalities (multi-omics from DNA/RNA to protein), at a lower cost and higher resolution (from bulk to single cell and spatial omics), through an expanded menu of applications to enable human genetics research using DNBSEQ CompleteWGS, spatial transcriptomics, proteomics, and single cell sequencing.

“Aligning with the industry’s demand to rapidly provide more data at a lower cost point, in 2024, our flagship high throughput sequencer, DNBSEQ-T7, gained good traction in the high throughput sequencing market,” said Rob Tarbox, VP of Product and Marketing at Complete Genomics.

At Booth #745, ASHG attendees can learn about whole genome sequencing (WGS) and spatial solutions, product highlights, new technology innovations, sequencing product demos, a menu of sequencing applications. To learn more and add the full program of speakers to your calendar, visit completegenomics.com/ASHG2024.

Complete Genomics will highlight the following product innovations:

DNBSEQ-G400RS FluoXpert: This new multifunctional sequencer merges high-throughput sequencing with multiplex immunofluorescence (mIF), enabling in vivo spatial protein detection and seamless multi-omics analysis for both DNA/RNA and protein data within one system.DNBSEQ-G800: A versatile benchtop sequencer designed for exceptional accuracy and extended read lengths enabling Q40 accuracy and single-end reads of 600 bp and beyond, it delivers the longest single read among short-read sequencers, powered by CoolMPS technology for improved variant calling for a range of demanding applications.DNBelab-D4 Digital Sample Preparation System: A portable, fully automated system for preparing libraries from DNA or RNA samples to DNA Nanoballs (DNBs) in about 2.5-3.5 hours. This enclosed system minimizes contamination and accelerates turnaround, making it ideal for metagenomics, targeted sequencing, whole genome sequencing and converting third-party libraries for DNBSEQ compatibility.DNBSEQ-G99 – Delivering Q40 data quality for a broad swath of sequencing applications, with two independent flow cells for up to 48 Gb in less than 12 hours for PE150 (from loading to FASTQ), or 96 Gb in 30 hours for PE300.Spatial transcriptomics – New agreement to be the exclusive distributor of STOmics products in the U.S. STOmics, which specializes in solutions for spatial multi-omics through an advanced spatiotemporal multi-omics platform, is differentiated with unbiased, high resolution, species agnostic, large field of view multi-omics solutions. Researchers interested in incorporating spatial transcriptomics into their research can apply to two targeted tracks of the Complete Genomics Spatial Xcellerator grant program.CompleteWGS – A comprehensive workflow solution that provides increased genomic coverage, improved sequencing of challenging genes, and haplotype phasing. The solution enables labs to routinely sequence genomes yielding high quality, comprehensive data in a cost-effective and scalable manner. The approach is powered by the proven accuracy of DNBSEQ sequencing technology.

Here are the highlighted expert talks that Complete Genomics will host at ASHG 2024:

CoLab: Wednesday, Nov. 6, 9:45 a.m. – 10:15 a.m., CoLab Theater 3

Speaker: Joe Yeong, MD, Ph.D., FRCPath (UK), Group Leader, IMCB, A*STAR, Division of Pathology, Singapore General Hospital

Topic: Unlocking True Spatial Multi-Omics (DNA-RNA-Protein) with GoSpatial, Stereo-seq, and FluoXpert: When 1 + 1 > 2

Industry Workshop: Thursday, Nov. 7, 12:00 – 1:00 p.m., Room 105, Denver Convention Center

Michael Snyder, Ph.D. – Director, Center for Genomics and Personalized Medicine, Stanford UniversityTopic: Cutting Edge Omics Discovery by DNBSEQ™ TechnologyGang Wu, Ph.D. – Director, Center for Applied Bioinformatics, St. Jude Children’s Research HospitalTopic: Using Linked-read Sequencing to Dissect Complex Rearrangements in Extrachromosomal DNASky Lee, Ph.D. – Associate Director, Genomics Shared Resource, University of Colorado AnschutzTopic: $350 Human WGS from Sample to Result with DNBSEQ-T7 Platform

Exploring Spatial Omics: Dinner & Workshop, Thursday, Nov. 7, 7:00 – 9:30 p.m., Capitol Five, Hyatt Regency

Speakers:

Yongfu Wang, Ph.D., Sr. Manager, Field & Sales Support for STOmics
Complete Genomics

Topic: Mapping the Future Omics: Stereo-seq for Single-cell Spatial Whole Transcriptome Profiling for Diverse Biological Applications

Hui Shen, Ph.D. Professor, Associate Director, Tulane Center for Biomedical Informatics and Genomics, Deming Department of Medicine, School of Medicine, Tulane University

Topic: Spatial Transcriptomic Analysis of Alzheimer’s Disease Using Stereo-seq

About Complete Genomics

Complete Genomics is a pioneering life sciences company that provides novel, end to end DNA sequencing solutions. It has been at the forefront of high throughput, cost-effective sequencing technology development since its inception in 2005. Our products have powered over 9,400 publications across a wide array of applications. To learn more, visit www.completegenomics.com.

* For Research Use Only. Not for use in diagnostic procedures.

View original content:https://www.prnewswire.com/news-releases/complete-genomics-highlights-innovation-with-expanded-multi-omics-and-spatial-transcriptomics-applications-at-ashg-2024-302295591.html

SOURCE Complete Genomics

Related Topics:
Continue Reading

Technology

MiniTool ShadowMaker 5.0 Introduces Cloud Sync for Google Drive and OneDrive

Published

41 minutes ago

on

October 23, 2026

By

VANCOUVER, BC, Oct. 22, 2026 /PRNewswire/ — MiniTool® Software Limited has announced the release of MiniTool ShadowMaker 5.0, the latest version of its Windows backup and file sync software. The update introduces a new Cloud Sync feature for Google Drive and OneDrive, along with enhancements to the registration and purchase experience, interface refinements, and compatibility fixes.

New Features and Improvements in MiniTool ShadowMaker 5.0

1. Cloud Sync to Google Drive and OneDrive

MiniTool ShadowMaker 5.0 introduces Cloud Sync, allowing users to synchronize files and folders from a Windows computer to Google Drive or OneDrive. Users can choose the files and folders they want to sync and select their preferred cloud storage service as the destination.

The new feature supports one-way synchronization from a local Windows PC to cloud storage, providing an additional way to save copies of important files outside of your computer. Together with MiniTool ShadowMaker’s existing local file sync function, Cloud Sync expands the available destinations for file sync.

2. Streamlined License & Plan Management

The latest update introduces an enhanced register interface that remains easily accessible even after activation. Registered users can now effortlessly review their current plan, explore upgrade options, or update their license key anytime for a smoother user experience.

These refinements are intended to improve usability when users manage their software registration and licensing.

3. Interface Refinements and Compatibility Fixes

MiniTool ShadowMaker 5.0 includes interface improvements and fixes for certain display issues. One notable fix addresses a blurry display issue that could occur on some systems equipped with AMD GPUs.

These changes focus on resolving specific issues and improving the user experience on affected systems.

4. Additional Improvements

Beyond Cloud Sync and the changes outlined above, MiniTool ShadowMaker 5.0 includes additional interface and functionality refinements. Together, these updates further improve the software’s usability while expanding its file synchronization options.

With support for Google Drive and OneDrive, MiniTool ShadowMaker 5.0 provides Windows users with another approach to manage file copies across local and cloud storage. Users who want to synchronize files to cloud storage can download the Free Edition and explore the new capabilities.

About MiniTool ShadowMaker

MiniTool ShadowMaker is a Windows backup and file sync solution designed to help users protect their operating systems and important data. It supports backing up Windows systems, disks, partitions, files, and folders to local drives, external hard drives, shared folders, and other supported locations. Users can select specific items to back up according to their needs.

For users who need to migrate data to another drive, MiniTool ShadowMaker offers a disk cloning feature. The software also supports restoring backed-up data and creating bootable media for system recovery.

By combining backup, file synchronization, disk cloning, and restore capabilities, MiniTool ShadowMaker offers Windows users a set of tools for data protection and system recovery.

About MiniTool® Software Limited

MiniTool Software Limited is a professional software company that develops computer applications. It provides software for partition management, data recovery, data backup and sync, video editing, multimedia conversion, and screen recording for home and business users. The company is committed to developing innovative, reliable, and easy-to-use software that simplifies everyday digital tasks.

View original content to download multimedia:https://www.prnewswire.com/news-releases/minitool-shadowmaker-5-0-introduces-cloud-sync-for-google-drive-and-onedrive-302916663.html

SOURCE MiniTool® Software Limited

Continue Reading

Technology

Rocket Companies to Announce Third Quarter 2026 Results on October 29, 2026

Published

2 hours ago

on

October 22, 2026

By

DETROIT, Oct. 22, 2026 /PRNewswire/ — Rocket Companies, Inc. (NYSE: RKT) (“Rocket Companies” or “the Company”), the Detroit-based homeownership platform, today announced that the Company will issue its third quarter 2026 earnings on October 29, 2026. Leadership will host a conference call to discuss results at 4:30 p.m. ET on that date. A press release detailing the Company’s results will be issued prior to the call.

A live webcast of the event will be available on the “Events & Presentations” section of the Company’s Investor Relations website at ir.rocketcompanies.com. A replay of the webcast will be available on the Investor Relations website following the event.

About Rocket Companies

Founded in 1985, Rocket Companies (NYSE: RKT) is a Detroit-based homeownership platform including mortgage, real estate and personal finance businesses: Rocket Mortgage, Redfin, Rocket Close, Rocket Money and Rocket Loans.

With insights from more than 160 million calls with clients each year, more than 30 petabytes of data and a mission to Help Everyone Home, Rocket Companies is well positioned to be the destination for AI-fueled homeownership.

For more information, please visit the Company’s Corporate website or Investor Relations website.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rocket-companies-to-announce-third-quarter-2026-results-on-october-29-2026-302917496.html

SOURCE Rocket Companies, Inc.

Continue Reading

Technology

Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister

Published

2 hours ago

on

October 22, 2026

By

SACRAMENTO, Calif., Oct. 22, 2026 /PRNewswire/ — Lunai Bioworks Inc. (Nasdaq: LNAI) (the “Company”) announced that on October 21, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company no longer complies with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2,500,000. The Company reported a stockholders’ deficit of $(9,024,946) in its Annual Report on Form 10-K for the fiscal year ended June 30, 2026, and does not meet the alternative market value of listed securities or net income standards. Because the Company is subject to a mandatory Hearings Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(B), Nasdaq staff determined to delist the Company’s securities. Trading in the Company’s common stock on Nasdaq is expected to be suspended at the opening of business on October 30, 2026.

The Company will not request a hearing. Rather than contest the staff determination, the Company’s Board of Directors approved on October 22, 2026 the voluntary withdrawal of the Company’s common stock from listing on Nasdaq under Rule 12d2-2(c) under the Securities Exchange Act of 1934, as amended. The Board took this action because of the staff determination and the Company’s financial condition, and concluded that the cost of continued listing and SEC reporting is not justified.

The Company notified Nasdaq of its intention on October 22, 2026. The Company intends to file a Form 25 with the Securities and Exchange Commission (the “SEC”) on or about November 2, 2026, and expects the delisting to become effective on or about November 12, 2026. The Company then intends to file a Form 15 to suspend its SEC reporting obligations, to the extent it is eligible to do so. The Company’s SEC reporting obligations will continue unless and until they are terminated or suspended in accordance with the SEC’s rules.

The Company does not intend to arrange for quotation of its common stock on any over-the-counter market and cannot assure that any trading market for its common stock will exist after trading on Nasdaq is suspended.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the expected suspension of trading, the expected timing of the Form 25 and Form 15 filings, and the expected timing of delisting and deregistration. Actual results may differ materially due to risks and uncertainties, including Nasdaq and SEC procedures and the Company’s financial condition. The Company undertakes no obligation to update these statements, except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-announces-receipt-of-nasdaq-determination-and-intention-to-voluntarily-delist-and-deregister-302917510.html

SOURCE Lunai Bioworks Inc.

Continue Reading

Trending